History

The Pioneers (1901-1953)

in 1901, Emil Fischer did something no one had done before -- he stitched two amino acids together in a lab and held up the result. he called the bond a "peptide" bond, from the Greek peptein, to digest. it was a tiny molecule -- glycylglycine, just two units long -- but it proved that the building blocks of life could be assembled by human hands, not just by cells.

twenty years later, the stakes got personal. Leonard Thompson, a 14-year-old in Toronto, was dying of type 1 diabetes -- a guaranteed death sentence in 1922. Banting and Best had just isolated a mysterious substance from dog pancreas. they injected Thompson with it. he recovered. insulin, a peptide hormone, became the first proof that understanding these molecules could save a human life.

but no one actually knew what insulin looked like -- its exact sequence of amino acids was a total mystery. Frederick Sanger spent 12 years on it, breaking the molecule apart with enzymes, identifying each fragment, and piecing the overlaps together like a jigsaw puzzle where you don't have the picture on the box. in 1953, he published the complete sequence -- the first protein ever fully mapped. it changed biology's fundamental assumption: proteins aren't random blobs. they're precise machines.

The Synthesis Revolution (1963-1982)

knowing the recipe for a peptide and actually building one from scratch were completely different problems. in the early 1960s, synthesizing even a short peptide meant months of painstaking solution chemistry -- add one amino acid, purify, add the next, purify again. Bruce Merrifield had a deceptively simple idea: anchor the first amino acid to a tiny resin bead so it can't wash away, then build the chain one link at a time without ever needing to isolate intermediates. his solid-phase technique cut synthesis from months to days and eventually won him the Nobel Prize.

then in 1977, biology became engineering. a startup called Genentech spliced a human gene into E. coli bacteria and coaxed them into producing somatostatin -- the first time a living cell was reprogrammed to manufacture a human peptide. five years later, the FDA approved Humulin -- human insulin grown in bacterial vats instead of harvested from pig pancreases. it was the first recombinant DNA drug ever sold, and it meant we no longer needed to borrow molecules from animals. we could just tell bacteria what to build.

The Discovery Era (1992-2005)

here's a question nobody was asking in the early 1990s: what's in Gila monster spit? John Eng, an endocrinologist at a Bronx VA hospital, was. he had a hunch that venomous animals -- creatures that need to rapidly disrupt their prey's metabolism -- might produce peptides worth studying. Gila monsters eat only three or four times a year, and their venom is packed with molecules that aggressively regulate blood sugar during those rare meals. Eng found one -- exendin-4 -- that mimicked human GLP-1, a hormone that triggers insulin release. the catch: your body's own GLP-1 breaks down in about two minutes. the lizard version lasted hours.

it took 13 years to get from venom to pharmacy shelf. in 2005, the FDA approved exenatide -- brand name Byetta -- the first GLP-1 receptor agonist drug, built directly from a molecule that evolved in a desert reptile. nobody knew it yet, but this was the seed of a $30 billion revolution.

The GLP-1 Revolution (2017-2024)

Novo Nordisk's engineers solved a problem that had plagued GLP-1 drugs for years: they break down too fast. their trick was attaching a fatty acid tail to semaglutide so it would hitch a ride on albumin -- a protein already circulating in your blood -- extending its half-life from hours to a full week. one injection, once a week. when Ozempic launched in 2017 for diabetes, it worked well. when higher-dose Wegovy launched in 2021 for obesity -- showing roughly 15% body weight loss -- it became a cultural phenomenon.

celebrities posted about it. demand exploded. shortages spread worldwide. then Eli Lilly raised the stakes: tirzepatide (Mounjaro) hit both GLP-1 and GIP receptors simultaneously, delivering up to 22.5% weight loss in trials. by 2024, GLP-1 drugs were generating over $30 billion a year, compounding pharmacies were racing to make copies, and the FDA was scrambling to draw new regulatory lines. in seven years, a niche diabetes drug class had reshaped how the world thinks about obesity.

What's Next?

three races are happening right now, and each one could change what peptide therapy looks like within the next few years.

the first is the end of needles. oral semaglutide proved a peptide can survive stomach acid, but barely -- it requires a special absorption enhancer and fasting. next-gen oral drugs like orforglipron and danuglipron are small-molecule GLP-1 agonists designed from scratch to be swallowed like aspirin. if they work, injections become optional.

the second race is stacking receptors. tirzepatide hits two. retatrutide hits three -- GLP-1, GIP, and glucagon receptors simultaneously -- and phase II trials showed 24% body weight loss. if phase III confirms those numbers, it would be the most effective weight-loss drug ever made. the third race is the strangest: AI-designed peptides. companies like Nuritas and Peptone are using machine learning to design molecules that evolution never produced -- optimized for stability, potency, and targets that no natural peptide has ever hit.

Knowledge Check

Test what you learned in this module.

Practice Exercises

Reinforce your understanding with interactive exercises.